Biopharma

Drug discovery concept petri dish
#AI / data analytics / healthtech / informatics #Biopharma #Business #Clinical trials #Drug discovery #Genetics / genomics #Genomics #Market reporting

What to expect from drug discovery and development in 2023

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year.   The Market After over two years of the Covid-19 pandemic, 2022 year was somewhat of a return to normal… Read More

#Exclusive Content

#Biopharma #Cell and gene therapy #Drug discovery #Stem cells

The use of base editing in stem cell-based therapies

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies.   Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential… Read More

#Exclusive Content

#Biopharma #Biopharmaceuticals #DNA #Synthetic biology

Why synthetic biology is the next big thing for biopharma 

Listen to this article on the DDW Podcast: ‘Can synthetic biology save us?’ and ‘synthetic biology can benefit us all’, are just some of the headlines this emerging scientific field has recently elicited. Lu Rahman speaks to Dr Emily Leproust, Founder and CEO of Twist Biopharma, about the potential that synthetic biology holds within… Read More

#Exclusive Content

#Analysis #Biopharma #Characterisation

The importance of glycan analysis and characterisation for biopharma

Professor Michael Butler, head of the National Institute for Bioprocessing Research and Training (NIBRT) Cell Technology Group (CTG), explains that the characterisation and analysis of glycans is important for the biopharma sector as it can help in the development of therapeutic agents such as monoclonal antibodies and other recombinant proteins. Read More

#Exclusive Content

#Biopharma #Digitalisation #Regulatory

The next steps for biopharma regulations

Following a decade of solid groundwork to modernise regulatory information management in life sciences, leading companies have now shifted their focus to how they might exploit this new digital landscape - to transform process management; improve data exchange with the enterprise at large; revisit organisational structures and roles, and enable… Read More

#Exclusive Content #Regulatory #Trends & Analysis

Organ-on-a-chip
#Biopharma #Microfluidics #Organ-on-a-chip

eBook: Using microfluidics in drug discovery

This 24-page DDW eBook, sponsored by Emulate Bio, contains exclusive insight from industry experts on: How microfluidics is fuelling innovation in drug discovery A detailed look at the organ-on-a-chip sector How human tissue chips are helping advance our understanding of biology This guide is free of charge and you can… Read More

#News

#Advanced Therapy Medicinal Products (ATMPs) #Biopharma #Cell and gene therapy #Cell and Gene Therapy Catapult

Cell and gene therapy – where is the innovation? 

Where globally is innovation occurring and what factors - industry, regulatory, and academia - are helping developers get their products to market? Here, DDW Editor Reece Armstrong explores the global hubs of innovation for cell and gene therapies. Since the approval of Kymirah in 2017, the cell and gene therapy… Read More

#Exclusive Content

#Biopharma #Infographic #iPSC

Infographic: Differentiating iPSCs – Which Approach Works Best?

Current methods to generate cells from human-induced pluripotent stem cells (iPSCs) lack reproducibility and scalability. This raises challenges for disease research, drug discovery and cell therapy development due to unreliable data and long experimental timelines. However, there is a new technology on the block, enabling reproducible, consistent and scalable production… Read More

#News

#Appointment #Biopharma #Neurology

TikoMed appoints new members to Board of Directors

Biopharmaceutical company TikoMed has announced two new appointments to its Board of Directors as the company focuses on its ILB drug programme. TikoMed has appointed Tara Heitner and Pete Zorn to its Board of Directors. Tara Heitner has more than 15 years of experience in the biopharmaceutical industry and has… Read More

#Business & Investment #News

Scientist looking through microscope
#Assay #Biologics / Biotechnology #Biopharma #Drug development #Ingredients / APIs / Fine chemicals

Addressing the challenge of salt forms in drug discovery

Listen to this article on the DDW Podcast: Some 5% of commercially available research compounds are sold as salt forms. These can have better properties than their parents, including preferable stability, solubility, bioavailability, and manufacturability. By selecting the correct salt form for an assay or as a reagent, scientists can optimise… Read More

#Exclusive Content #Opinion

#Biopharma #DNA #Drug discovery #Evonetix #Synthetic biology

Synthetic biology: Advancing drug discovery

This eBook, sponsored by Evonetix, contains exclusive insight from industry experts on how synthetic biology is innovating and advancing drug discovery.   Key topics include:   Four key approaches to synthetic biology  The global advances in synthetic biology drug discovery Why synthetic biology is the next big… Read More

#DDW eBooks

#Biopharma #Drug discovery #Evonetix #Organoids #Synthetic biology

Synthetic biology e-book out now  

This e-book, sponsored by Evonetix, contains exclusive insight from industry experts on how synthetic biology is innovating and advancing drug discovery.   Key topics include:   Four key approaches to synthetic biology  The global advances in synthetic biology drug discovery Why synthetic biology is the next big… Read More

#News

#Biopharma #Biotechnology #CDMO #Drug development

Why project management holds the key to efficient drug development

Listen to this article on the DDW Podcast: Ian Hollingsworth, Associate Director of product development at Boyds, the global drug development consultancy, explains the benefits to the drug development lifecycle of building strong partnerships with external consultants, and when and how to get the best from them. Everyone can benefit from… Read More

#Exclusive Content

Monoclonal antibody
#Biologics #Biopharma #Drug development

New ebook: The researcher’s guide to Dynamic Light Scattering

This e-book by NanoTemper looks at the workflows researchers are using in the biologics space and the benefits dynamic light scattering (DLS) offers. You will find out: What biologics are and why they’re important How DLS gives you information about your samples and what that data means Tips and… Read More

#News